Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enovis Corporation (NYSE: ENOV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Enovis describes itself as an innovation-driven medical technology growth company with two primary segments, Prevention & Recovery (P&R) and Reconstructive (Recon), and its filings offer detailed insight into how this orthopedic-focused business reports its financial condition, capital structure and governance matters.
Investors can review Form 8-K filings where Enovis reports material events, such as quarterly earnings releases, changes in senior leadership roles, amendments to its credit agreement and other significant corporate developments. For example, recent 8-Ks have covered second- and third-quarter financial results, a retirement transition for a senior human resources executive, and an amendment to the company’s credit agreement that adjusts maturity dates, leverage ratio thresholds and borrowing terms.
Beyond current reports, Enovis’ annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR) typically contain segment information for Prevention & Recovery and Reconstructive, discussions of non-GAAP measures such as adjusted EBITDA and adjusted net income, and risk factor disclosures that may reference acquisitions and integration, including the acquisition of Lima. These filings help explain how the company evaluates its performance and manages its medical technology portfolio.
Stock Titan enhances access to Enovis filings by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points in plain language. Users can quickly understand what a new 8-K, 10-Q or 10-K means for Enovis’ operations, capital structure or governance without reading every page. The platform also makes it easier to track items such as credit agreement amendments and other direct financial obligations that Enovis reports under the SEC’s requirements.
Enovis CORP senior vice president and chief legal officer Tandy Bradley J received a grant of 25,586 shares of common stock on March 9, 2026 as a compensation award. The award consists of restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date. On March 7, 2026, 1,874 shares were withheld by the company at $24.51 per share to satisfy tax withholding and remittance obligations related to net settlement of restricted stock units, and this did not represent an open-market sale. Following these transactions, Bradley directly holds 65,641 shares of Enovis common stock.
Enovis CORP senior vice president and CFO Phillip Benjamin (Ben) Berry received an equity grant of 47,974 shares of common stock through restricted stock units. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date, aligning his compensation with long-term company performance.
In a separate transaction, 3,167 shares were withheld by the company at a price of $24.51 per share to cover tax obligations tied to the net settlement of restricted stock units, which the company states does not represent a sale by Berry. Following these transactions, he holds 158,596 shares of Enovis common stock directly.
McDonald Damien reported acquisition or exercise transactions in this Form 4 filing.
Enovis Corp Chief Executive Officer Damien McDonald received an equity award of 143,923 shares of common stock as a grant at no cash cost on the date of grant. This award consists of restricted stock units that vest in three equal annual installments beginning on the first anniversary of the grant date. Following this grant, McDonald directly holds 246,676 shares of Enovis common stock.
Enovis Corp Chief Administrative Officer Oliver Engert bought a total of 1,750 shares of common stock in open-market transactions. He purchased 250 shares and 500 shares on March 6, 2026 at prices of $24.28 and $24.48 per share, and 1,000 shares on March 9, 2026 at $23.39 per share. Following these purchases, he directly owns 46,640 shares of Enovis common stock.
Enovis CORP senior executive reports tax-related share disposition
Enovis CORP SVP and Chief Legal Officer Bradley J. Tandy reported a Form 4 transaction involving 1,102 shares of common stock on March 4, 2026. The shares were withheld by the company at a price of $25.79 per share to cover tax withholding obligations tied to the net settlement of restricted stock units.
The footnote clarifies this was a tax-withholding disposition and not an open-market sale by the executive. After this transaction, Tandy directly owned 41,929 shares of Enovis common stock.
Enovis CORP executive reports tax-related share withholding. Group President, P&R Terry D. Ross reported a disposition of 765 shares of Enovis common stock on March 4, 2026 at $25.79 per share. These shares were withheld by the company to cover tax obligations from the net settlement of restricted stock units and are explicitly described as not representing a sale by the reporting person. After this withholding, Ross directly owns 34,606 shares of Enovis common stock.
Enovis Corp principal accounting officer John Kleckner reported a small tax-related share disposition. On the reported date, 442 shares of Enovis common stock at $25.79 per share were withheld by the company to cover tax obligations tied to the net settlement of restricted stock units, which the footnote states does not represent a sale by Kleckner. After this withholding, he held 11,545 shares directly.
Enovis CORP director Shirley Brady reported a tax-related share disposition. On March 4, 2026, 3,059 shares of Enovis common stock at $25.79 per share were withheld by the company to satisfy tax withholding obligations tied to restricted stock units.
The footnote explains this was not an open-market sale by Brady but a tax-withholding disposition in connection with net settlement of RSUs. After this transaction, Brady directly owned 101,243 Enovis shares.
Enovis CORP’s Senior Vice President and Chief Financial Officer Phillip Benjamin (Ben) Berry reported an automatic share disposition tied to equity compensation. On the Form 4, 2,220 shares of common stock at $25.79 per share were withheld by the company to satisfy tax withholding obligations upon net settlement of restricted stock units, as clarified in the footnote that this does not represent a sale by the reporting person. After this tax-withholding event, Berry’s directly held common stock position is 113,789 shares.
Enovis Corp executive Louis Vogt, Group President, Recon, reported a Form 4 transaction involving company common stock. On March 4, 2026, 888 shares were withheld by the company at $25.79 per share to cover tax obligations from the net settlement of restricted stock units. The footnote explains this was a tax-withholding event and not an open-market sale by Vogt. After this withholding, Vogt directly owned 34,608 shares of Enovis common stock.